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Retinal vein occlusion (RVO) is a major cause of vision loss. Of the two main types of RVO, branch retinal vein occlusion (BRVO)
is 4 to 6 times more prevalent than central retinal vein occlusion (CRVO). A basic risk factor for RVO is advancing age. Further risk
factors include systemic conditions like hypertension, arteriosclerosis, diabetes mellitus, hyperlipidemia, vascular cerebral stroke,
blood hyperviscosity, and thrombophilia. A strong risk factor for RVO is the metabolic syndrome (hypertension, diabetes mellitus,
and hyperlipidemia). Individuals with end-organ damage caused by diabetes mellitus and hypertension have greatly increased risk
for RVO. Socioeconomic status seems to be a risk factor too. American blacks are more often diagnosed with RVO than non-
Hispanic whites. Females are, according to some studies, at lower risk than men. The role of thrombophilic risk factors in RVO is
still controversial. Congenital thrombophilic diseases like factor V Leiden mutation, hyperhomocysteinemia and anticardiolipin
antibodies increase the risk of RVO. Cigarette smoking also increases the risk of RVO as do systemic inflammatory conditions like
vasculitis and Behcet disease. Ophthalmic risk factors for RVO are ocular hypertension and glaucoma, higher ocular perfusion
pressure, and changes in the retinal arteries.
1. Introduction
Retinal vein occlusion (RVO) is the second most common
retinal vascular disease after diabetic retinopathy. There are
two types of RVO: branch retinal vein occlusion (BRVO)
and central retinal vein occlusion (CRVO). BRVO is more
common than CRVO. In BRVO there is occlusion of a branch
of the retinal vein system, while, in CRVO, occlusion is
located in the central retinal vein [1, 2]. Hayreh divided
RVO into three types: (1) BRVO is divided further into
major BRVO and macular BRVO; (2) CRVO is divided into
ischemic and nonischemic types; and (3) hemi-CRVO with
involvement of only one half of the retina surface and like
CRVO is divided into ischemic and nonischemic types [3].
RVO is more prevalent in men than women and is more
frequent in older age (over 65 years). The International
Eye Disease Consortium published a paper in 2010 that
reported the prevalence of RVO in theUSA, Europe,Asia, and
Australia [4]. The combined pooled data contained 68,751
individuals from 15 studies, with participants’ ages ranging
from 30 to 101 years.The prevalence of RVOwas 5.20 per 1000
(confidence interval (CI), 4.40–5.99) for any RVO, 4.42 per
1000 (CI, 3.65–5.19) for BRVO, and 0.80 per 1000 (CI, 0.61–
0.99) for CRVO [4]. This shows that BRVO is 4 times more
common than CRVO. In one study, the prevalence was found
to vary by race/ethnicity and increased with age but did not
differ according to gender [4]. This provides summary data
on the prevalence of RVO and suggests that approximately
16 million people may have this condition. Research on
preventive and treatment strategies for this sight threatening
eye disease is needed [4]. The Beijing Eye Study states, on the
basis of a sample of 4439 patients, that the 10-year incidence
of BRVO is 1.6 per 100 subjects (43 subjects (88% of patients
with RVO); 44 eyes), and the incidence of CRVO was 0.3 per
100 persons. The mean age (in 2001) was 56.9 ± 10.2 years
(range, 40–80 years), and mean refractive error was −0.64
± 2.30 diopters (range, −10.25 to +2.75 diopters). Macular
edema was present in 30% of BRVO cases [5].
Its pathogenesis is still not completely understood. The
condition may be due to a combination of three systemic
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changes known as Virchow’s triad: (1) hemodynamic changes
(venous stasis), (2) degenerative changes of the vessel wall,
and (3) blood hypercoagulability [6].
Due to its multifactorial nature, treatment of RVO is
still a challenge. To date, however, no causal treatment has
been shown in large randomized studies to be effective [6].
A number of therapies have been assessed in the treatment
of RVO (laser photocoagulation, intravitreal steroids and
anti-VEGF agents, surgical procedures—pars plana vitrec-
tomy and systemic treatments—hemodilution, anticoagula-
tion therapy, and fibrinolysis) [6].
2. Risk Factors for RVO
RVO has many known ophthalmic and systemic risk factors.
As we know from its pathogenesis, Virchow’s triad is impor-
tant: hemodynamic changes (venous stasis), degenerative
changes of the vessel wall, and blood hypercoagulability.
Known risk factors are summarized in Table 1.
The most recognized risk factors for RVO are age and
systemic vascular disorders. In over half of the cases, the age
of onset is over 65 years. However, patients under 45 can also
develop an RVO [6].
2.1. Systemic Risk Factors for RVO. Systemic diseases such
as HTN, HLD, and DM are very strongly associated with
the development of RVO [8]. The data of published studies
suggest that 48% of RVO is connected to NTH, 20% to
HLD, and 5% to DM [9]. Cigarette smoking has also been
linked to RVO [10].The Diabetes Control and Complications
Study (DCCT) and Blue Mountains Study also reported that
HTN,HLD, arteriosclerosis, andDM are risk factors for RVO
[11, 12]. Schmidt on small sample of patients with RVO in
combination with retinal artery occlusion (RAO) described
a variety of systemic risk factors. Systemic risk factors were
present in 11 out of 14 subjects (mainly HTN 8x, HLD 3x, and
chronic smoking 3x) [13].
3. Central Retinal Vein Occlusion (CRVO)
3.1. Systemic Risk Factors for CRVO. Data have also recently
been published on risk factors connected with CRVO [14].
The authors identified risk factors associated with CRVO
among a diverse group of patients throughout the United
States. A total of 494 165 subjects met the study inclusion
criteria. The mean age of this CRVO study population was
69.6 years. CRVO were diagnosed in 1302 subjects; 667
(51.2%) were female, and the racial distribution included 1017
whites (78.1%), 94 blacks (7.2%), 51 Latinos (3.9%), 13 Asians
(1.0%), 7 of other races (0.54%), and 120 whose race was not
documented (9.2%) [14]. There were no gender differences.
The white race predominated.
3.2. Socioeconomic Factors for CRVO. American blacks had
increased risk by 58% of CRVO being diagnosed compared
with non-Hispanic whites (adjusted hazard ratio (HR), 1.58;
95% confidence interval (CI), 1.25–1.99). There was no sta-
tistically significant increased risk for CRVO in Latinos and
Asians compared to non-Hispanic whites. Women were 25%
Table 1: Systemic and ocular risk factors for RVO [5, 7].
Systemic risk factors Ocular risk factors
Hypertension Glaucoma
Diabetes mellitus Decreased ocular perfusionpressure
Hyperlipidemia
External retrobulbar
compression-orbital
neoplasma and endocrine
orbitopathy
Atherosclerotic associated
diseases: ischemic heart disease,
obesitas (high body mass
index), and cigarette smoking
Retinal arteriolar
signs-focal arteriolar
narrowing and
arteriovenous nicking
Systemic vasculitis: systemic
lupus erythematosus,
sarcoidosis, and syphilis
Hematologic neoplasia:
polycythaemia vera, multiple
myeloma, and leukemia
Hypercoagulation diseases:
antifosfolipid syndrome and
protein S deficiency
Drug therapy: oral
contraceptives, diuretics, and
hypotensive drugs
less likely than men to have CRVO (HR, 0.75; 95% CI, 0.66–
0.85) [14].
3.3. Systemic Diseases Associated with CRVO. Themajority of
people diagnosed with CRVO hadmore than 1 component of
themetabolic syndrome, defined as the presence of coexisting
HTN, DM, and HLD [14]. Metabolic syndrome was diag-
nosed in 487 subjects with CRVO (37.4%). By comparison,
142 101 individuals (28.8%) who were not diagnosed with
CRVO had the metabolic syndrome [14]. Further systemic
risk factors for CRVO identified in this study instead of the
metabolic syndrome were separately diagnosed HTN, DM,
HLD, further, peripheral artery disease (PAD), myocardial
infarction (MI), deep venous thrombosis (DVT), pulmonary
embolism (PE), and a hypercoagulable stage. Statistically
significant differences were found in all the above-mentioned
conditions between two groups (subjects with and without
CRVO). Subjects with diagnosed CRVO were more likely
to have all the above systemic risk factors. The authors
used a regression model to assess the relationship between
components of the metabolic syndrome (HTN, DM, and
HLD) individually and in combination with the risk of
CRVO. HTN increases the risk of CRVO by 66%. Subjects
with DM alone (no HTN or HLD) or HLD alone (no DM
or HTN) had no increased risk of CRVO. Individuals with
all 3 metabolic syndrome components had a 58% increased
risk of developing CRVO relative to those with none of these
conditions [14].
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Risk factors connected with vascular diseases include
patients with prior stroke (44% increased risk) (HR, 1.44; 95%
CI, 1.23–1.68).Those with PAD had a 15% increased hazard of
CRVO (HR, 1.15; 95% CI, 1.00–1.33). Risk of CRVO was very
strongly increased in subjects with proven hypercoagulable
stage. These subjects had 145% higher risk of CRVO (HR,
2.45; 95% CI, 1.40–4.28). Surprisingly, subjects with DVT
and PE had no increased risk of CRVO (HR, 0.86; 95% CI,
0.55–1.34). A priorMI actually had decreased hazard of being
diagnosed with CRVO (HR, 0.72; 95% CI, 0.57–0.92). Use
of anticoagulants surprisingly did not decrease the risk of
development of CRVO (𝑃 = 0.60) [14].
3.4. Severity of Systemic Disease. One study examined
whether severity of HTN and DM had any impact on the risk
of developing CRVO. The authors found that subjects with
noncomplicatedHTNhad a 36% increased risk of developing
CRVO. Moreover, subjects with advanced HTN had 92%
increased risk of CRVO [14]. Participants with no end-organ
damage caused by DM were not at increased risk for CRVO
(HR, 0.87; 95% CI, 0.73–1.04) but those with end-organ
damage fromDMhad a 53% increased hazard of CRVO (HR,
1.53; 95% CI, 1.28–1.84) DM [14].
Can we generalize the results of this survey regarding
the risk of developing CRVO? The authors emphasized that
HTN is a major risk factor. Other risk factors are less clearly
defined but we can say that advanced DM also increases the
risk of CRVO [14]. For both conditions (HTN and DM),
common is the increased risk of systemic arteriosclerosis,
which is generally considered the main pathophysiological
component of developing RVO. Advanced DM is risk factor
for CRVO, compared to DM without complications that do
not increase the risk of CRVO. HLD is not a risk factor for
developing CRVO. The presence of other arterial diseases
such as PAD and vascular cerebral stroke increases the risk
of CRVO.The role of hypercoagulability is still controversial.
Coagulopathies like factor V deficiency are more prevalent
in younger subjects. Socioeconomic factors play a role in
blacks [14]. The higher risk for CRVO in blacks compared to
whites can be further attributed to the higher prevalence of
glaucoma in blacks [14].
3.5. Ocular Risk Factors for CRVO. One main ocular risk
factor associated with CRVO is glaucoma [11]. The Chinese
study published by Zhou in 2013 (10-year incidence of RVO
from2001 to 2011) updated the association ofmain risk factors
for RVO in a Chinese population. Very strong association
with RVO was shown with lower ocular pressure resulting in
venous stasis (part ofWirchow’s triad) (𝑃 = 0.02). In contrast,
increased RVO risk was not associated with refractive error
(𝑃 = 0.74), high myopia (above 8 diopters) (𝑃 = 0.55),
intraocular pressure measured in 2001 (𝑃 = 0.39), 2006
(𝑃 = 0.85), and 2011 (𝑃 = 0.99), central cornea thickness
(𝑃 = 0.23), anterior chamber depth (𝑃 = 0.07), lens thickness
(𝑃 = 0.56) or axial length (𝑃 = 0.26), or glaucoma in 2006
(𝑃 = 0.30) [5]. Lower ocular pressure may be connected
either with glaucoma or with systemic risk factors like HLD,
DM, and arteriosclerosis.
4. Branch Retinal Vein Occlusion (BRVO)
The recent published meta-analysis of Jaulim et al. showed
pooled data on main and subsidiary risk factors connected
to BRVO [15]. BRVO was, as stated before, 4 to 6 times more
common than CRVO. Meta-analysis showed a prevalence of
BRVO in 0.5–1.2% [3, 4, 10, 12, 16, 17]. Advancing age is also
a very important risk factor for RVO. The meta-analysis by
Rogers et al. [4] showed a 1.57 per 1,000 prevalence of BRVOs
in 40-to-49-year olds (4.58 per 1,000), in 50-to-59-year olds
(11.11 per 1,000), and in 60-to-69-year olds, 12.76 per 1,000 in
70-to-79-year olds, and 10.32 per 1,000 in those older than
80 years. The prevalence in subjects older than 80 is 7 times
higher than people from 40 to 49 years [4].
The main pathogenic mechanism for development of
BRVO is arterial stiffness that causes venous compression in
the common adventitial sheath [17–19].
4.1. Risk Factors for BRVO. Systemic vascular diseases like
HTN, HLD, and PAD and metabolic diseases like DM are
very strongly connected with BRVO. Ameta-analysis showed
that, in BRVO, the odds ratio for HTN is 3.0 (95% CI: 2.0–
4.4), for HLD 2.3 (95% CI: 1.5–3.5), and for diabetes mellitus
(DM) 1.1 (95% CI: 0.8–1.5) [20]. In a study published by
Lam et al. risk factors for developing BRVO in 60 patients
younger than 50 years were very similar to those in older
people (HTN, HLD, and high body mass index) [21]. It is
not completely clear what role thrombophilia plays in BRVO
pathogenesis. Blood abnormalities play a controversial role
in the pathogenesis of BRVO; erythrocyte volume, level of
fibrinogen, and hematocrit appear to be important [22].
Recent meta-analyses of RVO and thrombophilic factors
by Zhou et al., J. Rehak and M. Rehak, and Janssen et al.
showed that only hyperhomocysteinemia and anticardio-
lipin antibodies play a role in the pathogenesis of RVO [6, 17,
23].
5. Association of RVO with Thrombophilia
and Other Hematologic Risk Factors
Yau et al. recommended that coagulopathy and throm-
bophilia should also be considered where no obvious RVO
etiology is found or if the patient is young or has bilateral
RVO, a history of thrombosis, or a family history of throm-
bosis [7].
Based on RVO in younger patients, risk factors that
predispose to coagulation abnormalities have been studied
in detail. Published data on thrombophilic abnormalities in
RVO patients have accumulated recently but these reports
consist of small studies and case reports based on retrospec-
tive information on patients retrieved from clinical databases
[24–26]. Prospective studies on the association between
thrombophilic factors and RVO are rare [9].
The role of thrombophilic risk factors in RVO is still
controversial. Various studies have shown conflicting results.
High levels of plasma homocysteine and a well-recognized
risk factor for arterial and venous thrombotic events, as
well as low levels of vitamin B6 and folic acid, have been
identified as independent risk factors for RVO [27]. Systemic
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inflammatory conditions like vasculitis and Behcet disease
may increase the risk of RVO [3, 10]. A number of studies
have reported that increased blood viscosity, factor V Leiden
mutation, hyperhomocysteinemia, and protein C or S defi-
ciencymay play a role in the development of CRVO [6, 17, 26,
28, 29]. Glueck et al. in a case control study identified elevated
homocysteine and factor V Leiden mutation as risk factors
but found no association of anticardiolipin antibodies or
lupus anticoagulant with CRVO [28]. Janssen et al. confirmed
in a meta-analysis of thrombophilic risk factors that elevated
homocysteine and anticardiolipin antibodies seem to be
associated with CRVO [30]. Di Capua et al. in a recent large
case control study found no association between CRVO and
thrombophilic risk factors, including homocysteine levels
and anticardiolipin antibodies [31]. Recurrent CRVO has
also been reported with elevated homocysteine levels in one
study but associations with anticardiolipin antibodies and
factor V Leiden mutation were not identified as risk factors
in a multivariate study comparing patients with recurrent
CRVO to those with one CRVO [31]. Given the conflicting
findings, the specific roles of various thrombophilic fac-
tors and hypercoagulability in CRVO need further study
[9].
6. Conclusion
RVO exists in two subtypes: CRVO (central retinal vein
occlusion), which is less common and represents occlusion
of central retinal vein, and BRVO (branch retinal vein
occlusion), which is 4–6 times more common and represents
occlusion of some branches of central retinal vein.
RVO is the secondmost common retinal vascular disease
after diabetic retinopathy. RVO is a relatively common and
frequently devastating cause of visual loss mainly in older
patients. Its prevalence varies according to studies in overall
populations from 5.2 to 16 per 1000.
Visual acuity is primarily decreased due to macular
edema and retinal ischemia. Although it was first recognized
over a century ago, the exact pathogenesis remains unclear,
despite a variety of systemic and ophthalmic risk factors
that have been identified. A basic risk factor for RVO is
advanced age. The risk is further connected with systemic
conditions like HTN, arteriosclerosis, DM, HLD, vascular
cerebral stroke, blood hyperviscosity, and thrombophilia.
The metabolic syndrome (HTN, DM, and HLD) is a strong
risk factor for RVO. Individuals with end-organ damage
caused by diabetes mellitus and hypertension have strongly
increased risk for RVO. Race seems to be also risk factor for
RVO. Blacks are more often diagnosed with RVO than non-
Hispanic whites. Females are, according to some studies, at
lower RVO risk. The role of thrombophilic risk factors in
RVO is still controversial. Congenital thrombophilic diseases
like factor V Leiden mutation, hyperhomocysteinemia, and
anticardiolipin antibodies increase the risk of RVO. Cigarette
smoking also increases risk of RVO. Systemic inflammatory
conditions like vasculitis and Behcet disease increase the risk.
Ophthalmic risk factors for RVO are ocular hypertension and
glaucoma, lower ocular perfusion pressure, and congenital
and acquired changes in retinal arteries.
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